All In MedTech

FDA Clearance Tracker · P170012

HEMOBLAST™ Bellows

Premarket approval (PMA) is the pathway for the highest-risk devices. FDA reviews clinical evidence of safety and effectiveness before approving.

Last checked: Nov 20, 2026Latest source record: Dec 15, 2017 (this decision)Source: openFDAMethods & limitations

PMA

Decided

Dec 15, 2017

Approved

Time to decision

260 days

Received Mar 30, 2017. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA

Device class

Class III

The decision

FDA number
P170012
Device name
HEMOBLAST™ Bellows
Applicant location
Newport News, VA
Received
Mar 30, 2017
Decided
Dec 15, 2017
Decision
Approved
Supplements
32 in FDA's data for this PMA. See them on the FDA record

Device type

Device class
Class III
Regulation
21 CFR 878.4490

Every decision under product code PMX

FDA's approval statement

As written in FDA's record.

Approval of the Hemoblast Bellows. This device is indicated for surgical procedures as an adjunct to hemostasis when control of minimal, mild, and moderate bleeding by conventional procedures is ineffective or impractical, except in neurosurgical, ophthalmic, and urological procedures.

How new is this?

These are facts about FDA's records. They are not a judgment about the device.

  • It is not the first decision under product code PMX. The earliest in FDA's data is P990009, decided Dec 8, 1999.
  • It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.

Source documents

Other decisions for Dilon Technologies, Inc.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

No other decisions since 2015 under this exact applicant name.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.